CASE REPORT
Spontaneous pathological splenic rupture as a first manifestation of mantle cell lymphoma – a case report and literature review
1
Students’ Scientific Association in the Department of General and Transplant Surgery, Medical University of Łódź, Łódź, Poland
2
Department of General and Transplant Surgery, Medical University of Łódź, Łódź, Poland
3
Department of Pathology, Chair of Oncology, Medical University of Łódź, Łódź, Poland
Submission date: 2025-03-04
Final revision date: 2025-08-30
Acceptance date: 2025-09-02
Publication date: 2025-11-28
Pol J Pathol 2025;76(3):261-266
KEYWORDS
TOPICS
ABSTRACT
Splenic rupture is a critical surgical condition that poses an immediate threat to the patient’s life. In most cases, mechanical trauma to the organ results in the rupture of the capsule, leading to hemorrhage into the peritoneal cavity. Spontaneous (pathological) spleen rupture (SPSR) is considered when the etiology of the rupture is non-traumatic. Spontaneous (pathological) spleen rupture is most commonly associated with hematological malignancies, though it remains a rare condition. Only 8 cases have been caused by mantle cell lymphoma (MCL). This review presents the case of a 59-year-old male patient who was treated with emergency splenectomy due to SPSR. Histopathological examination revealed MCL.
REFERENCES (32)
1.
Giagounidis AA, Burk M, Meckenstock G, Koch AJ, Schnei- der W. Pathologic rupture of the spleen in hematologic malignancies: two additional cases. Ann Hematol 1996; 73: 297-302.
2.
Williams J, Chiruka S. Spontaneous splenic rupture and rituximab-induced acute thrombocytopenia in a patient with high-risk mantle cell lymphoma. Case Rep Haematol 2019; 2019: 2429098.
3.
Lunning MA, Stetler-Stevenson M, Silberstein PT, Zenger V, Marti GE. Spontaneous (pathological) splenic rupture in a blastic variant of mantle cell lymphoma: a case report and literature review. Clin Lymphoma 2002; 3: 117-120.
4.
American Society of Haematology. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
5.
Szymczyk M. Chłoniak z komórek płaszcza. In: Walewski J. Nowotwory układu chłonnego. Centrum Medyczne Kształcenia Podyplomowego, Warszawa 2011.
6.
Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416-3423.
7.
Navarro A, Bea S, Pedro J, Campo E. Molecular pathogenesis of mantle cell lymphoma. Hematol Oncol Clin N Am 2020; 34: 795-807.
8.
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organisation subtypes. CA Cancer J Clin 2016; 66: 443-459.
9.
Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, et al. Incidence trends of mantle cell lymphoma in United States between 1992 and 2004. Cancer 2008; 113: 791-798.
10.
SEER Cancer Stat Facts: non-Hodgkin lymphoma. National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/statfa... (accesed: 09.09.2024).
11.
Pittaluga S, Verhoef G, Criel A, Maes A, Nuyts J, Boogaerts M, et al. Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma 1996; 21: 115-125.
12.
Perry DA, Bast MA, Armitage JO, Weisenburger DD. Diffuse intermediate lymphocytic lymphoma. A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. Cancer 1990; 66: 1995-2000.
13.
Jaffe ES, Bookman MA, Longo DL. Lymphocytic lymphoma of intermediate differentiation-- mantle zone lymphoma: a distinct subtype of B-cell lymphoma. Hum Pathol 1987; 18: 877-880.
14.
De Oliveira MS, Jaffe ES, Catovsky D. Leukaemic phase of mantle zone (intermediate) lymphoma: its characterisation in 11 cases. J Clin Pathol 1989; 42: 962-972.
15.
Vadlamudi G, Lionetti KA, Greenberg S, Mehta K. Leukemic phase of mantle cell lymphoma two case reports and review of the literature. Arch Pathol LAb Med 1996; 120: 35-40.
16.
Duggan MJ, Weisenburger DD, Ye YL, Bast MA, Pierson JL, Linder J, et al. Mantle zone lymphoma. A clinicopathologic study of 22 cases. Cancer 1990; 66: 522-529.
17.
Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZ, et al. Mantle cell lymphoma: natural history defined in aserially biopsied population over a 20-year period. Ann Oncol 1995; 6: 249-256.
18.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
19.
Xu J, Medeiros LJ, Saksena A, Wang M, Zhou J, Li J, et al. CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. Oncotarget 2018; 9: 11441-11450.
20.
Stenzel A, Żuryn A, Grzanka AA, Grzanka A. Cykliny jako markery chorób nowotworowych. J Oncol 2012; 62: 115-122.
21.
Tan CB, Dhyan R, Sumreen M, Ahmed S, Freedman L, Mustacchia P. Pathologic rupture of the spleen in mantle-cell-type non-Hodgkin’s lymphoma. Case Rep Med 2012; 2012: 351275.
22.
Tondini C, Zanini M, Lombardi F, Bengala C, Rocca A, Giardini R, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s lymphomas. J Clin Onkol 1993; 11: 720-725.
23.
National Cancer Institute at the National Institute of health. Available from :https://www.cancer.gov/types/l... (accessed: 09.09.2024).
24.
Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood 2013; 121: 48-53.
25.
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, et al. 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 2016; 175: 410-418.
26.
Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo – purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
27.
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016; 388: 565-575.
28.
Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015; 26: 2323-2328.
29.
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017; 377: 1250-1260.
30.
Rule S. The modern approach to mantle cell lymphoma. Hematol Oncol 2019; 1: 66-69.
31.
Silkenstedt E, Dreyling M. Mantle cell lymphoma-advances in molecular biology, prognostication and treatment approaches. Hematol Oncol 2021; 1: 31-38.
32.
Rubin LG, Schaffner W. Clinical practice. Care of the asplenic patient. N Engl J Med 2014; 371: 349-356.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
